These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21500543)

  • 1. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
    Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Packaging, amplification, and appraisal of the recombinant tumor-selective type I herpes simplex virus carrying GALV.fus gene.
    Bing Z; Jianru Y; Yuequan J; Shifeng C; Xinping F
    Cell Biochem Biophys; 2014 Sep; 70(1):321-6. PubMed ID: 24687598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy of lung adenocarcinoma using herpes virus expressing a fusogenic membrane glycoprotein.
    Zhu B; Yang JR; Jiang YQ; Chen SF; Fu XP
    Cell Biochem Biophys; 2014 Jul; 69(3):583-7. PubMed ID: 24510538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of gene therapy with GALV membrane fusion glycoprotein in lung adenocarcinoma.
    Zhu B; Yang JR; Fu XP; Jiang YQ
    Cell Biochem Biophys; 2014 Jul; 69(3):577-82. PubMed ID: 24519667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
    Zhang J; Frolov I; Russell SJ
    J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
    Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
    J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
    Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
    Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].
    Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
    Ai Zheng; 2004 Jul; 23(7):788-93. PubMed ID: 15248913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
    Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
    Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An experimental study on targeting suicide gene therapy for lung cancer with HSV-TK driven by hTERT promoter].
    Wang YP; Tang XJ; Zhou QH; Che GW; Chen XH; Zhu DX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):701-5. PubMed ID: 19024294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
    Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
    Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
    Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
    Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
    Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
    Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer.
    Nakamori M; Fu X; Pettaway CA; Zhang X
    Prostate; 2004 Jun; 60(1):53-60. PubMed ID: 15129429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental studies on human lung cancer gene-therapy with HSV-TK/GCV system].
    Sha H; Wang E; Bao G
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):265-7. PubMed ID: 11326946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
    Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
    Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.